Czech antibody discovery company AbCheck is now in a research collaboration with Pierre Fabre under which AbCheck will use its AbSieve discovery platform to deliver antibodies against targets provided by the French firm. Pierre Fabre will have full rights to any antibodies selected and will make milestone payments and fees for discovery to AbCheck.
AbCheck says its AbSieve discovery platform combines its phage and yeast display technologies to develop antibodies in formats including full length IgGs as well as customer-specific and novel antibody formats. Its phage display libraries, according to the firm, allow for the discovery of specific high-affinity human antibodies for target proteins; the yeast display technology allows the selection of drug candidates with high affinities and improved drugability from a range of variants.
Pierre Fabre Pharmaceuticals' president Frédéric Duchesne said in a statement that this agreement should strengthen the firm's oncology portfolio along with its acquisition of immuno-oncological cancer therapeutic AUNP-12 from Aurigene back in February.
"Pierre Fabre Immunology Center is working on new promising targets and this collaboration will accelerate our antibody discovery," added Nathalie Corvaïa, Ph.D., managing director of the Pierre Fabre Immunology Center. "We are always looking to reinforce our capabilities through collaborations with platforms of excellence."